Other Corporate Information – Page 7

2022-11-09

Alligator Bioscience & Aptevo Therapeutics Announce Publication Highlighting ALG.APV-527 Preclinical Data in Peer-Reviewed Journal Molecular Cancer Therapeutics

ALG.APV-527 Demonstrates Favorable Preclinical Efficacy and Safety Compared to a First Generation 4-1BB Antibody ALG.APV-527 Rapidly Progres ...

2022-11-08

Study to evaluate AC101 (HLX22) in combination with anti-PD-1 antibody serplulimab, trastuzumab and chemotherapy in gastric cancer Phase 2 c ...

2022-11-02

Article shows CD40 x TAA bispecific antibodies can induce enhanced T cell cross-priming superior to monospecific CD40 antibodies using in vi ...

2022-11-01

Lund, Sweden, November 1, 2022 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces that senior company representatives wi ...

2022-10-17

Lund, Sweden – Alligator Bioscience AB (Nasdaq Stockholm: ATORX) will host a conference call (in English) for investors, analysts and media ...

2022-10-10

Lund, Sweden, October 10, 2022 – Alligator Bioscience AB (Nasdaq Stockholm: ATORX) today announced that Mattias Levin, PhD, Sr Team Ma ...

2022-09-30

• ATOR-1017 demonstrated excellent safety and tolerability at doses up to 900 mg • Stable disease as best tumor response reconfirms previous ...

2022-09-192022-09-19

Drug Candidate progressing to the clinic for evaluation in the treatment of 5T4-expressing tumor antigens in multiple solid tumor types. Lun ...

2022-09-14

Data from Phase 1b dose escalation part of the study shows that mitazalimab combined with mFOLFIRINOX is safe and well tolerated 900 µg/kg d ...